Dynavax Technologies Corporation (0IDA.L)
USD 14.02
(-3.7%)
USD 14.02
(-3.7%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -37.02 Million USD | -113.06% |
| 2022 | 283.52 Million USD | 110.82% |
| 2021 | 134.48 Million USD | 278.79% |
| 2020 | -75.22 Million USD | 38.08% |
| 2019 | -121.48 Million USD | 20.76% |
| 2018 | -153.31 Million USD | -59.7% |
| 2017 | -96 Million USD | 13.28% |
| 2016 | -110.7 Million USD | -5.36% |
| 2015 | -105.07 Million USD | -15.07% |
| 2014 | -91.31 Million USD | -37.33% |
| 2013 | -66.48 Million USD | 1.64% |
| 2012 | -67.59 Million USD | -42.08% |
| 2011 | -47.57 Million USD | 0.03% |
| 2010 | -47.58 Million USD | -214.85% |
| 2009 | -15.11 Million USD | 37.33% |
| 2008 | -24.12 Million USD | 66.07% |
| 2007 | -71.09 Million USD | -9.4% |
| 2006 | -64.98 Million USD | -188.94% |
| 2005 | -22.49 Million USD | -33.39% |
| 2004 | -16.86 Million USD | 5.09% |
| 2003 | -17.76 Million USD | 4.8% |
| 2002 | -18.65 Million USD | 4.46% |
| 2001 | -19.53 Million USD | -102.1% |
| 2000 | -9.66 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 6.06 Million USD | 136.55% |
| 2024 Q1 | -16.57 Million USD | -95.27% |
| 2023 Q4 | -8.49 Million USD | -265.97% |
| 2023 Q3 | 5.11 Million USD | 250.25% |
| 2023 Q2 | -3.4 Million USD | 81.01% |
| 2023 Q1 | -17.93 Million USD | -128.41% |
| 2023 FY | -37.02 Million USD | -113.06% |
| 2022 FY | 283.52 Million USD | 110.82% |
| 2022 Q4 | 63.13 Million USD | 2.83% |
| 2022 Q1 | 30.76 Million USD | -61.89% |
| 2022 Q2 | 128.22 Million USD | 316.82% |
| 2022 Q3 | 61.39 Million USD | -52.12% |
| 2021 Q4 | 80.71 Million USD | 402.35% |
| 2021 Q1 | 28.52 Million USD | 339.84% |
| 2021 Q2 | 9.17 Million USD | -67.85% |
| 2021 Q3 | 16.06 Million USD | 75.19% |
| 2021 FY | 134.48 Million USD | 278.79% |
| 2020 Q4 | -11.89 Million USD | 13.96% |
| 2020 FY | -75.22 Million USD | 38.08% |
| 2020 Q3 | -13.82 Million USD | 40.76% |
| 2020 Q1 | -19.31 Million USD | 29.49% |
| 2020 Q2 | -23.33 Million USD | -20.85% |
| 2019 Q2 | -38.97 Million USD | -2.95% |
| 2019 FY | -121.48 Million USD | 20.76% |
| 2019 Q1 | -37.85 Million USD | 0.28% |
| 2019 Q3 | -30.62 Million USD | 21.41% |
| 2019 Q4 | -27.38 Million USD | 10.58% |
| 2018 Q3 | -38.89 Million USD | -1.97% |
| 2018 FY | -153.31 Million USD | -59.7% |
| 2018 Q4 | -37.96 Million USD | 2.41% |
| 2018 Q1 | -38.31 Million USD | -37.62% |
| 2018 Q2 | -38.14 Million USD | 0.44% |
| 2017 Q4 | -27.84 Million USD | -24.34% |
| 2017 Q2 | -20.32 Million USD | 20.16% |
| 2017 Q3 | -22.39 Million USD | -10.19% |
| 2017 Q1 | -25.45 Million USD | -31.73% |
| 2017 FY | -96 Million USD | 13.28% |
| 2016 Q4 | -19.32 Million USD | 44.54% |
| 2016 Q2 | -29.25 Million USD | -7.18% |
| 2016 Q1 | -27.29 Million USD | -1.29% |
| 2016 FY | -110.7 Million USD | -5.36% |
| 2016 Q3 | -34.83 Million USD | -19.09% |
| 2015 Q4 | -26.94 Million USD | 5.26% |
| 2015 Q3 | -28.44 Million USD | -22.41% |
| 2015 FY | -105.07 Million USD | -15.07% |
| 2015 Q2 | -23.23 Million USD | 12.17% |
| 2015 Q1 | -26.45 Million USD | -18.02% |
| 2014 Q1 | -13.96 Million USD | -7.5% |
| 2014 FY | -91.31 Million USD | -37.33% |
| 2014 Q2 | -24.85 Million USD | -77.95% |
| 2014 Q4 | -22.41 Million USD | 25.48% |
| 2014 Q3 | -30.07 Million USD | -21.01% |
| 2013 Q2 | -17.04 Million USD | 18.34% |
| 2013 Q4 | -12.99 Million USD | 16.55% |
| 2013 FY | -66.48 Million USD | 1.64% |
| 2013 Q3 | -15.56 Million USD | 8.69% |
| 2013 Q1 | -20.87 Million USD | -4.38% |
| 2012 FY | -67.59 Million USD | -42.08% |
| 2012 Q1 | -15.84 Million USD | -234.77% |
| 2012 Q2 | -14.64 Million USD | 7.57% |
| 2012 Q3 | -17.09 Million USD | -16.71% |
| 2012 Q4 | -20 Million USD | -16.99% |
| 2011 Q4 | -4.73 Million USD | 68.06% |
| 2011 Q3 | -14.82 Million USD | -46.79% |
| 2011 Q2 | -10.09 Million USD | 43.68% |
| 2011 Q1 | -17.92 Million USD | -14.81% |
| 2011 FY | -47.57 Million USD | 0.03% |
| 2010 Q2 | -16.27 Million USD | -81.79% |
| 2010 FY | -47.58 Million USD | -214.85% |
| 2010 Q4 | -15.61 Million USD | -131.3% |
| 2010 Q3 | -6.75 Million USD | 58.51% |
| 2010 Q1 | -8.95 Million USD | 22.93% |
| 2009 FY | -15.11 Million USD | 37.33% |
| 2009 Q1 | 4.34 Million USD | 129.55% |
| 2009 Q2 | 2.86 Million USD | -33.99% |
| 2009 Q3 | -10.71 Million USD | -473.6% |
| 2009 Q4 | -11.61 Million USD | -8.43% |
| 2008 FY | -24.12 Million USD | 66.07% |
| 2008 Q4 | 1.89 Million USD | 132.86% |
| 2008 Q3 | -5.75 Million USD | 13.21% |
| 2008 Q2 | -6.63 Million USD | 51.31% |
| 2008 Q1 | -13.62 Million USD | 2.82% |
| 2007 Q2 | -21.82 Million USD | -35.72% |
| 2007 Q1 | -16.07 Million USD | 26.88% |
| 2007 Q3 | -19.17 Million USD | 12.13% |
| 2007 Q4 | -14.01 Million USD | 26.9% |
| 2007 FY | -71.09 Million USD | -9.4% |
| 2006 Q4 | -21.99 Million USD | -36.62% |
| 2006 FY | -64.98 Million USD | -188.94% |
| 2006 Q1 | -8.9 Million USD | 5.93% |
| 2006 Q3 | -16.09 Million USD | 10.52% |
| 2006 Q2 | -17.98 Million USD | -101.96% |
| 2005 Q1 | 4.7 Million USD | 185.59% |
| 2005 FY | -22.49 Million USD | -33.39% |
| 2005 Q4 | -9.46 Million USD | -8.68% |
| 2005 Q3 | -8.71 Million USD | 3.34% |
| 2005 Q2 | -9.01 Million USD | -291.64% |
| 2004 Q4 | -5.49 Million USD | -28.24% |
| 2004 FY | -16.86 Million USD | 5.09% |
| 2004 Q3 | -4.28 Million USD | -38.45% |
| 2004 Q2 | -3.09 Million USD | 22.33% |
| 2004 Q1 | -3.98 Million USD | 77.72% |
| 2003 FY | -17.76 Million USD | 4.8% |
| 2003 Q4 | -17.88 Million USD | -77852.17% |
| 2003 Q1 | -4.71 Million USD | 0.0% |
| 2003 Q2 | 96 Thousand USD | 102.03% |
| 2003 Q3 | 23 Thousand USD | -76.04% |
| 2002 FY | -18.65 Million USD | 4.46% |
| 2001 FY | -19.53 Million USD | -102.1% |
| 2000 FY | -9.66 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 119.043% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 61.967% |
| Myriad Genetics, Inc. | -123.7 Million USD | 70.066% |
| Evolus, Inc. | -49.23 Million USD | 24.79% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 89.532% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 102.743% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 90.542% |
| uniQure N.V. | -282.87 Million USD | 86.91% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 33.589% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 86.584% |
| bluebird bio, Inc. | -244.26 Million USD | 84.841% |
| Abeona Therapeutics Inc. | -48.2 Million USD | 23.178% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 86.878% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 134.515% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 49.618% |
| Editas Medicine, Inc. | -169.18 Million USD | 78.113% |
| FibroGen, Inc. | -281.81 Million USD | 86.861% |
| Geron Corporation | -193.94 Million USD | 80.908% |
| Blueprint Medicines Corporation | -486.27 Million USD | 92.385% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 101.873% |
| Illumina, Inc. | -1.06 Billion USD | 96.536% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 91.96% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 5.427% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 114.758% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 69.523% |
| Adicet Bio, Inc. | -152.03 Million USD | 75.646% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 86.175% |
| Insmed Incorporated | -709.62 Million USD | 94.782% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 92.814% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 103.406% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 17.102% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -602.752% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.737% |
| Waters Corporation | 817.67 Million USD | 104.528% |
| Zoetis Inc. | 3.06 Billion USD | 101.207% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.54% |
| Biogen Inc. | 1.29 Billion USD | 102.855% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 86.486% |
| Nektar Therapeutics | -137.42 Million USD | 73.056% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 63.276% |
| Perrigo Company plc | 151.9 Million USD | 124.377% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 84.028% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 66.525% |
| Verastem, Inc. | -92.08 Million USD | 59.789% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.86% |
| Imunon, Inc. | -21.03 Million USD | -76.069% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 17.857% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 76.197% |
| Homology Medicines, Inc. | -48.25 Million USD | 23.266% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.915% |
| OPKO Health, Inc. | -157.02 Million USD | 76.418% |
| Exelixis, Inc. | 170.88 Million USD | 121.668% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 110.969% |
| TG Therapeutics, Inc. | 20.63 Million USD | 279.46% |
| Incyte Corporation | 620.52 Million USD | 105.967% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 94.903% |